Therapeutic digestive endoscopy II

Urban, Ondřej; Falt, Přemysl

doi:10.36290/vnl.2018.095

Cited by 1 publication

(2 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Local tissue dilatation indicates endoscopic balloon dilatation (EBD), endoscopic stent placement, peroral endoscopic myotomy (POEM), etc., which are less invasive surgical techniques to manage malignant or benign strictures in the digestive tract. With rapid advancement in hemostatic material and surgical therapeutic modality, [ 96 ] MIS today is capable to examine the whole gastrointestinal tract, respiratory tract, and solid organ in vivo in a safer and shorter operation time. Some technically combined treatments become capable of probing and intervening the bile duct, pancreatic duct, [ 27a ] and diverticular hemorrhage at high risk.…”

Section: Minimally Invasive Surgery and Nano‐hemostat Solutionmentioning

confidence: 99%

“…In gastric surgery, peptic ulcers are the most common cause of UGIB. Endoscopic therapy is a well‐recognized gold standard for evaluating and treating peptic ulcer‐related lesions or bleeds, [ 96b ] including the diagnosis and bleeding treatment of duodenal ulcers (DU). [ 97 ] To achieve effective peptic ulcer resection in surgery, intraoperative hemostasis is a potent curative option in surgical treatments except that delayed or recurrent bleeding and ulcer perforation are common complications in patients.…”

Section: Clinical or Preclinical Use Of Dsap Biomaterials In Surgical...mentioning

confidence: 99%

See 1 more Smart Citation

Short Peptide Nanofiber Biomaterials Ameliorate Local Hemostatic Capacity of Surgical Materials and Intraoperative Hemostatic Applications in Clinics

et al. 2023

View full text Add to dashboard Cite

Short designer self‐assembling peptide (dSAP) biomaterials are a new addition to the hemostat group. It may provide a diverse and robust toolbox for surgeons to integrate wound microenvironment with much safer and stronger hemostatic capacity than conventional materials and hemostatic agents. Especially in noncompressible torso hemorrhage (NCTH), diffuse mucosal surface bleeding, and internal medical bleeding (IMB), with respect to the optimal hemostatic formulation, dSAP biomaterials are the ingenious nanofiber alternatives to make bioactive neural scaffold, nasal packing, large mucosal surface coverage in gastrointestinal surgery (esophagus, gastric lesion, duodenum, and lower digestive tract), epicardiac cell‐delivery carrier, transparent matrix barrier, and so on. Herein, in multiple surgical specialties, dSAP‐biomaterial‐based nano‐hemostats achieve safe, effective, and immediate hemostasis, facile wound healing, and potentially reduce the risks in delayed bleeding, rebleeding, post‐operative bleeding, or related complications. The biosafety in vivo, bleeding indications, tissue‐sealing quality, surgical feasibility, and local usability are addressed comprehensively and sequentially and pursued to develop useful surgical techniques with better hemostatic performance. Here, the state of the art and all‐round advancements of nano‐hemostatic approaches in surgery are provided. Relevant critical insights will inspire exciting investigations on peptide nanotechnology, next‐generation biomaterials, and better promising prospects in clinics.

show abstract

Section: Minimally Invasive Surgery and Nano‐hemostat Solutionmentioning

confidence: 99%

Section: Clinical or Preclinical Use Of Dsap Biomaterials In Surgical...mentioning

confidence: 99%